OncoGenex unveils positive survival results from Apatorsen phase 2 trial in metastatic bladder cance
OncoGenex Pharmaceuticals has unveiled positive survival results from the final analysis of the Phase 2 Borealis-2 trial of apatorsen in combination with docetaxel treatment that enrolled 200 patients with metastatic bladder cancer whose disease had progressed following first-line platinum-based chemotherapy.
